Phio Pharmaceuticals Corp. PHIO 深 沪
等待开盘 08-28 09:30:00 美东时间
1.12
-0.080
-6.67%
华盛通- 最 高1.21
- 今 开1.21
- 成交量 24.35万股
- 最 低 1.10
- 昨 收 1.20
- 总市值 1.30万
- 52周最高 4.1899
- 市盈率 静 --
- 换手率 2095.93%
- 52周最低 0.8127
- 委 比 98.88%
- 总股本 1.16万
- 历史最高 3118.50
- 量 比 1.12
- 振 幅 9.17%
- 历史最低 0.8127
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
08-26 20:10
Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will ...
06-25 19:19
Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of $(0.47) per share from the
05-08 04:51
Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply
Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous carcinomas. In its Phase 1b trial, Phio has reported that 22 patients completed treatment
03-30 19:22
Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b clinical study (NCT
03-23 19:17
